Clinical trials
Venous Thrombosis trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
73 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 5 |
| 2007 | 5 |
| 2008 | 7 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 3 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 47 |
| Unknown status | 13 |
| Terminated | 8 |
| Active, not recruiting | 3 |
| Recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bayer | 9 |
| Bristol-Myers Squibb | 5 |
| Sanofi | 4 |
| University of Padova | 4 |
| Daiichi Sankyo | 3 |
| GlaxoSmithKline | 3 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 3 |
| University Of Perugia | 3 |
| Anthos Therapeutics, Inc. | 2 |
| Azienda Ospedaliera Universitaria Policlinico | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Venous Thrombosis | 73 |
| Pulmonary Embolism | 27 |
| Venous Thromboembolism | 22 |
| Thrombosis | 9 |
| Neoplasms | 5 |
| Embolism and Thrombosis | 4 |
| Embolism | 3 |
| Thromboembolism | 3 |
| Atrial Fibrillation | 2 |
| Cardiovascular Diseases | 2 |
Trials
Showing 51 to 73 of 73. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.